CC-292

DRUG5 trials

Sponsors

Celgene, Celgene Corporation

Conditions

Healthy VolunteersLeukemia Lymphocytic Chronic B-CellLymphoma, Large B-Cell, DiffuseRheumatoid Arthritis

Phase 1

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

CompletedNCT01732861

CelgeneLeukemia Lymphocytic Chronic B-Cell

Start: 2012-12-28End: 2019-01-23Updated: 2019-12-20

Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CompletedNCT01744626

Celgene CorporationLeukemia Lymphocytic Chronic B-Cell

Start: 2012-12-31End: 2015-12-31Updated: 2016-04-19

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

TerminatedNCT02031419

CelgeneLymphoma, Large B-Cell, Diffuse

Start: 2013-12-18End: 2023-12-12Updated: 2024-01-18

Relative Bioavailability Study of CC-292

CompletedNCT02433457

CelgeneHealthy Volunteers

Start: 2014-05-26End: 2014-09-26Updated: 2020-08-13

Phase 2

Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

CompletedNCT01975610

CelgeneRheumatoid Arthritis

Start: 2013-10-31End: 2016-02-29Updated: 2017-07-31

Related Papers

An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.

2022-06-03

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma

eJHaem2022-02-1415 citations

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma

eJHaem2022-01-146 citations

Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study.

2019-11-1343 citations

Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood2019-11-13

Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse

Blood2019-11-13

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Blood2018-11-297 citations

Avadomide (CC-122) Alters T Cell Repertoire and Enhances Infiltration of Lymphocytes into Tumor Microenvironment in DLBCL Patients

Blood2018-11-292 citations